Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection. A variety of in vitro assays for the detection of SARS-CoV-2 neutralizing antibodies has been described. However, validation of the different assays against each other is important to allow comparison of different studies. Here, we compared four different SARS-CoV-2 neutralization assays using the same set of patient samples. Two assays used replication competent SARS-CoV-2, a focus forming assay and a TCID 50 -based assay, while the other two assays used replication defective lentiviral or vesicular stomatitis virus (VSV)-based particles pseudotyped with SARS-CoV-2 spike. All assays were robust and produced highly reproducible neutralization titers. Titers of neutralizing antibodies correlated well between the different assays and with the titers of SARS-CoV-2 S-protein binding antibodies detected in an ELISA. Our study showed that commonly used SARS-CoV-2 neutralization assays are robust and that results obtained with different assays are comparable.
【저자키워드】 SARS-CoV-2, Neutralizing antibodies, Neutralization assay, pseudotype virus, 【초록키워드】 neutralizing antibody, antibody, Infection, virus, ELISA, Particle, Replication, In vitro assay, titer, Patient, vaccine candidate, vesicular stomatitis virus, SARS-CoV-2 neutralization, SARS-CoV-2 neutralizing antibody, neutralization titers, SARS-CoV-2 spike, S-protein, binding antibody, novel coronavirus SARS-CoV-2, TCID, pseudotyped, effective, robust, produced, described, variety, correlated, induce, comparable, competent, lentiviral, focus forming assay,